This article is more than 5 years old. Information may no longer be current.

Inotek begins enrollment for phase 1 trial of IOP-lowering drug

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BEVERLY, Mass. — Inotek Pharmaceuticals has begun enrolling patients in a phase 1 clinical trial evaluating the safety, tolerability and IOP-lowering potential of INO-8875, a selective adenosine-1 agonist for treating glaucoma, the company announced in a press release.

Inotek received U.S. Food and Drug Administration approval to advance the drug into clinical trials in March, the release said.

"New mechanisms for lowering IOP are needed to provide physicians with alternatives for the treatment of this chronic and progressive ocular disease — especially given the expanding population of glaucoma patients," Rudolf Baumgartner, MD, Inotek's chief medical officer, said. "Highly selective adenosine-1 receptor agonists, such as ours, may provide a meaningful new approach for the management of glaucoma."

The company also has other drugs in preclinical development for treating ophthalmic disorders, including diabetic retinopathy, age-related macular degeneration and uveitis, according to the release.